Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes
Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes
复制标题
DOI：
10.3892/etm.2016.3544
复制
发表时间：
2016-09-01
影响因子：
2.7
通讯作者：
Xu, Hongmei
中科院分区：
文献类型：
--
作者：
Hu, Jianxia;Wang, Yangang;Xu, Hongmei
细胞疗法为2型糖尿病（T2 DM）的治疗提供了新的机会。本研究评价了静脉输注沃顿商学院来源的间充质干细胞（WJ-MSC）治疗2型糖尿病的长期疗效和安全性。将61例T2 DM患者在基础治疗的基础上随机分为两组，I组患者静脉输注WJ-MSC 2次，间隔4周，II组患者静脉输注生理盐水作为对照。在36个月的随访期内，记录并评价任何不良反应的发生以及临床和实验室检查结果。组I中急性或慢性不良反应的缺乏与组II一致。在36个月的随访中，与II组相比，I组的血糖、糖化血红蛋白、C肽、胰岛细胞功能的稳态模型评估以及糖尿病并发症的发生率均显著改善。本研究的结果表明，输注WJ-MSC改善了胰岛细胞的功能，降低了糖尿病并发症的发生率，尽管确切的机制尚未阐明。WJ-MSC的输注可能是治疗2型糖尿病患者的有效选择。
Cellular therapies offer novel opportunities for the treatment of type 2 diabetes mellitus (T2DM). The present study evaluated the long-term efficacy and safety of infusion of Wharton's jelly-derived mesenchymal stem cells (WJ-MSC) on T2DM. A total of 61 patients with T2DM were randomly divided into two groups on the basis of basal therapy; patients in group I were administered WJ-MSC intravenous infusion twice, with a four-week interval, and patients in group II were treated with normal saline as control. During the 36-month follow-up period, the occurrence of any adverse effects and the results of clinical and laboratory examinations were recorded and evaluated. The lack of acute or chronic adverse effects in group I was consistent with group II.. Blood glucose, glycosylated hemoglobin, C-peptide, homeostasis model assessment of pancreatic islet -cell function and incidence of diabetic complications in group I were significantly improved, as compared with group II during the 36-month follow-up. The results of the present study demonstrated that infusion of WJ-MSC improved the function of islet -cells and reduced the incidence of diabetic complications, although the precise mechanisms are yet to be elucidated. The infusion of WJ-MSC may be an effective option for the treatment of patients with type 2 diabetes.